In cancer patients with ACS and thrombocytopenia, aspirin therapy was associated with a 90% 7-day survival rate compared to 6% without aspirin (P<0.0001), with no severe bleeding complications.
Cohort
Does aspirin therapy improve 7-day survival in cancer patients with acute coronary syndromes and thrombocytopenia?
Aspirin therapy significantly improves short-term survival in cancer patients experiencing ACS, even in the presence of thrombocytopenia, without increasing severe bleeding risk.
Absolute Event Rate: 90% vs 6%
p-value: p=< .0001
BACKGROUND: Patients with cancer who have thrombocytopenia may experience acute coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of bleeding. The purpose of this study was to test the hypothesis that the benefit of ASA therapy in the treatment of ACS would extend to cancer patients with thrombocytopenia and outweigh the risks of severe bleeding. METHODS: The records of all cancer patients diagnosed with an ACS in 2001 and referred for cardiology consultation were reviewed. Patients were divided into 2 groups on the basis of platelet count, >100 cells k/microL and 100 cells k/microL) who received ASA had a 7-day survival rate of 88% compared with 45% in those who did not receive ASA (P = .0096). CONCLUSIONS: Therapy with ASA was associated with a significantly improved 7-day survival after ACS in cancer patients, with or without thrombocytopenia, and not associated with more severe bleeding.
Sarkiss et al. (Wed,) conducted a cohort in Cancer with acute coronary syndromes and thrombocytopenia. Aspirin (ASA) vs. No aspirin was evaluated on 7-day survival rate in patients with thrombocytopenia (p=< .0001). In cancer patients with ACS and thrombocytopenia, aspirin therapy was associated with a 90% 7-day survival rate compared to 6% without aspirin (P<0.0001), with no severe bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: